LETTERS

Correspondence in relation to critical appraisal by Chapman *et al*

We write to raise some of a number of serious concerns about the recent paper 'Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal'.¹ We believe that it is written in a misleading fashion and contains important errors of fact, presentation and inference.

Tabulated data for symptoms, reliever use and exacerbations are presented only for patients randomly assigned to SMART. The lead author had access to the analysis by Bateman *et al*² that included full comparative data, as he wrote an accompanying editorial³ and cited it in the present paper. It is unscientific, knowing that symptoms and reliever use outcomes are remarkably similar for fixed-dose and SMART, to not present all the data. It is worse then to imply that fixed-dose, even at the highest approved and marketed doses, achieved target levels of control in the populations studied.

The Cochrane review by Cates and Lasserson,⁴ limited to comparisons of SMART compared with inhaled corticosteroid monotherapy, is wrongly invoked to support the contention that SMART does not reduce exacerbations compared with current best practice. Furthermore, the Cochrane authors' conclusions are selectively edited, removing their definition of current best practice and the qualifying phrase 'although results of five large trials are awaiting full publication'. Chapman and his co-authors are clearly aware of these data. Another Cochrane review that did examine SMART compared with fixed-dose combination therapy, concluding that SMART reduces severe exacerbations requiring oral corticosteroids but not hospitalisation, is not mentioned.⁵

Suggesting that SMART is proved to be associated with concerning airway inflammation is similarly disingenuous and is inconsistent with key messages constructed by the authors.⁶ It is misleading to omit to say that eosinophil counts were in the range of control, that there was no difference in the number of patients who would have been eligible, per protocol, for a maintenance dose increase or decrease, and that fixed-dose combination treatment did not achieve greater improvement in any other asthma endpoint despite more than double the inhaled corticosteroid dose.

This paper purports to be a critical analysis and is published under 'Review' in the table of contents. The authors could have presented a balanced description of peer-reviewed evidence, robustly discussing the pros and cons of different medication regimens in clinical practice, but did not. Misrepresentation of scientific evidence is of grave concern. The appropriate response is for the paper to be retracted.

Matthew J Peters, Christine R Jenkins

Concord Hospital, Department of Thoracic Medicine, Australia

Correspondence to Dr Matthew Peters, Department of Thoracic Medicine, Concord Hospital, Hospital Rd, Concord NSW 2139, Australia; matthew.peters@sswhs.nsw.gov.au

Competing interests MJP has received honoraria for participation on advisory boards and for CME presentations from AstraZeneca and GlaxoSmithKline. The quantum of involvement is significantly greater for AstraZeneca. CRJ has received honoraria for participation on advisory boards and for CME presentations from AstraZeneca, GlaxoSmithKline, Novartis, Bayer and Nycomed.

Provenance and peer review Not commissioned; not externally peer reviewed.

Accepted 24 September 2010

Published Online First 19 November 2010

Thorax 2011;**66**:86. doi:10.1136/thx.2010.149633

REFERENCES

1. Chapman KR, Barnes NC, Greening AP, *et al*. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. *Thorax* 2010;**65**:747–52.
2. Bateman ED, Reddel HK, Eriksson G, *et al*. Overall asthma control: the relationship between current control and future risk. *J Allergy Clin Immunol* 2010;**125**:600–8.
3. Chapman KR. SMART isn't. *J Allergy Clin Immunol* 2010;**125**:609–10.
4. Cates CJ, Lasserson TJ. Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. *Cochrane Database Syst Rev* 2009;(2):CD007313.
5. Cates CJ, Lasserson TJ. Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children (Review). *Cochrane Database Syst Rev* 2009;(2):CD007085.
6. Pavord ID, Jeffery PK, Qiu Y, *et al*. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. *J Allergy Clin Immunol* 2009;**123**:1083–9.

Single maintenance and reliever therapy (SMART) of asthma

We write to raise concerns about the recent paper by Chapman *et al* on single maintenance and reliever therapy (SMART) of asthma,¹ on the basis that it misrepresents published scientific evidence. The errors include:

1. Reporting outcome measures for one treatment arm from several double-blind studies (table 1 and accompanying text), but omitting the published data² for comparator arms from the same studies which would have been highly relevant to the authors' conclusions.
2. Selective omission of data from a peer-reviewed study³ that would have avoided the authors' doubts about the validity of double-blind double-dummy methodology.

3. Selective citing of text from one Cochrane review,⁴ with juxtaposition of text to imply that its conclusions were relevant to the studies described immediately before, and failure to cite a more relevant Cochrane review.⁵
4. Criticism of peer-reviewed publications on the basis of the use of outcome measures which were standard for other randomised controlled trials in asthma at the time (eg, criteria for exacerbations), or on the basis of omission of outcome measures which were either not available (eg, the adherence device used in a 1994 publication) or which have already been reported in a peer-reviewed publication (eg, a composite measure of asthma control²).

Misrepresentation of scientific evidence, whether in a data paper or a review, damages the scientific credibility of a journal. It is difficult to understand how the above errors could have passed through the usually rigorous *Thorax* peer review system, and this should be a matter of concern to the Editorial Board. The errors in the article, given their number and nature, cannot be addressed by simply publishing an erratum. We call on *Thorax* to respond appropriately.

Helen K Reddel,^{1,2} Kwok Y Yan²

¹Woolcock Institute of Medical Research, Sydney, Australia; ²Royal Prince Alfred Hospital, Camperdown, Australia

Correspondence to Helen Reddel, Associate Professor, Woolcock Institute of Medical Research, P O Box M77, Missenden Rd Post Office, NSW 2050, Australia; hkr@med.usyd.edu.au

Competing interests HR has received research funding from GlaxoSmithKline and AstraZeneca and honoraria for consulting, participation on advisory boards and/or continuing medical education presentations from AstraZeneca, GlaxoSmithKline, Merck, Getz, Novartis, Biota and Boehringer Ingelheim. KY has received honoraria from GlaxoSmithKline, AstraZeneca, Nycomed and Schering Plough for lectures and participation on advisory boards.

Provenance and peer review Not commissioned; not externally peer reviewed.

Accepted 27 August 2010

Published Online First 19 November 2010

Thorax 2011;**66**:86–87. doi:10.1136/thx.2010.149773

REFERENCES

1. Chapman KR, Barnes NC, Greening AP, *et al*. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. *Thorax* 2010;**65**:747–52.
2. Bateman ED, Reddel HK, Eriksson G, *et al*. Overall asthma control: the relationship between current control and future risk. *J Allergy Clin Immunol* 2010;**125**:600–8.
3. Kuna P, Peters MJ, Manjra AI, *et al*. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. *Int J Clin Pract* 2007;**61**:725–36.